This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Systemic Sclerosis Treatment Market

Market Insights on Systemic Sclerosis Treatment covering sales outlook, demand forecast & up-to-date key trends

Systemic Sclerosis Treatment Market by Therapeutics, Disease Type, End User & Region - Forecast 2022 - 2032

Systemic Sclerosis Treatment Market

The global systemic sclerosis treatment market size is expected to reach US$ 3.8 Billion in 2022. The increasing development of first-in-class therapies by prominent companies is anticipated to augur well for the global market. As per Future Market Insights (FMI), the market is likely to be valued at US$ 7.1 Billion in 2032 and exhibit growth at a considerable CAGR of 5.9% in the forecast period from 2022 to 2032.

Report Attribute

Details

Systemic Sclerosis Treatment Market Estimated Base Year Value (2021)

US$ 2.3 Billion

Systemic Sclerosis Treatment Market Expected Market Value (2022)

US$ 3.8 Billion

Systemic Sclerosis Treatment Market Anticipated Forecast Value (2032)

US$ 7.1 Billion

Systemic Sclerosis Treatment Market Projected Growth Rate (2022-2032)

5.9% CAGR

Systemic sclerosis is considered to be a rare autoimmune disorder that leads to atypical growth of connective tissues. These tissues become stiff and thick, which results in pain and swelling.

It also causes changes to the appearance and texture of the skin owing to high collagen production. It often leads to an immune response that destroys healthy tissues.

However, the disorder is not only confined to skin changes, but can also affect and individual’s kidneys, blood vessels, lungs, digestive system, heart, and muscles. The prevalence of this condition is projected to range from 50 to 300 cases per 1 million people.

Why is Off-label Drug Use Boosting the Systemic Sclerosis Treatment Market

Supplemental approvals for existing treatment options are likely to bolster the systemic sclerosis treatment market growth in future years. The increasing off-label use of numerous drugs approved for symptomatic indications, such as rheumatoid arthritis is also set to drive the market.

In addition to that, the rising prevalence of off-label drug use and the lack of curative therapies worldwide are expected to fuel the growth in this market. Many renowned companies are aiming to submit their applications for the approval for new drug therapies, which is another crucial factor that is estimated to aid the growth.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Factors May Restrain the Systemic Sclerosis Treatment Market Growth

The lack of validated results associated with various treatment options of systemic sclerosis may hinder the growth in this market. Many clinical trials that were conducted to evaluate systemic scleroderma therapeutics failed due to certain issues, which is likely to decline the demand for systemic sclerosis treatment options.

How is the North America Systemic Sclerosis Treatment Market Faring

North America is anticipated to generate the largest systemic sclerosis treatment market share of about 18.5% in the forecast period. This growth is attributable to the availability of recently developed immunosuppressants and the presence of a favorable reimbursement scenario across the U.S.

It is estimated that the prevalence of systemic sclerosis is 20 cases per million population in the U.S. The high healthcare expenditure in this country is also likely to drive the regional market. Besides, the presence of a large number of significant pharmaceutical companies in the U.S. is set to bode well for the North America market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What is the Europe Systemic Sclerosis Treatment Market Outlook

The increasing usage of biosimilars and generics in the U.K., Italy, and Germany for the treatment of systemic scleroderma is likely to push sales of systemic sclerosis treatment options across Europe. The increasing launch of small molecules and cutting-edge biologics for the treatment of systemic sclerosis is another vital factor that is projected to drive the regional market.

Furthermore, the high unmet medical needs are expected to create new growth opportunities for key players operating in Europe. The surging popularity of immunosuppressants owing to their high efficacy, as compared to mycophenolate mofetil, methotrexate, and methotrexate is likely to aid growth in this region.

Market Competition

Some of the leading companies operating in the global systemic sclerosis treatment market include Sanofi, Actelion Pharmaceuticals, Inc., Pfizer, Inc., Gilead Sciences, Inc., Cytori Therapeutics, Inc., Eli Lilly, Bayer AG, Boehringer Ingelheim, and Asta Pharma among others.

The market consists of various pharmaceutical companies that are currently striving to acquire a larger market share. To do so, they are engaging in partnerships, acquisitions, and mergers with other key players. Meanwhile, some of the other companies are increasingly focusing on launching immunosuppressants for the treatment of scleroderma induced ILD and PAH.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute

Details

Growth Rate

CAGR of 5.9% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Therapeutics
  • Disease Type
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Sanofi
  • Actelion Pharmaceuticals, Inc. Pfizer, Inc.
  • Gilead Sciences, Inc.
  • Cytori Therapeutics, Inc.
  • Eli Lilly
  • Bayer AG
  • Boehringer Ingelheim
  • Asta Pharma

Customization

Available Upon Request

Key Segments Profiled in the Systemic Sclerosis Treatment Industry Survey

By Therapeutics:

  • Corticosteroids
  • Immunosuppressant
  • Non-steroidal Anti-inflammatory Drugs
  • Blood Pressure Medication
  • Light Therapy
  • Nitroglycerin Ointment
  • Others

By Disease Type:

  • Limited Cutaneous Systemic Sclerosis
  • Diffuse Cutaneous Systemic Sclerosis

By End User:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Frequently Asked Questions

The global systemic sclerosis treatment market is anticipated to surpass US$ 7.1 Billion in 2032.

North America is set to lead the systemic sclerosis treatment market in the forecast period by generating a share of 18.5%.

Sanofi, Acelion Pharmaceuticals, Inc., Pfizer, Inc., Gilead Sciences, Inc., Cytori Therapeutics, Inc., Eli Lilly, Bayer AG, Boehringer Ingelheim, and Asta Pharma are some of the renowned companies in the systemic sclerosis treatment market.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Hemophilia Treatment Market

Published : February 2022

Healthcare

Hirschsprung Disease Treatment Market

Published : September 2017

Healthcare

Kids Sports Injury Treatment Market

Published : January 2016

Healthcare

Leukemia Therapeutics Treatment Market

Published : February 2022

Google translate

Systemic Sclerosis Treatment Market